江南化工(002226.SZ):完成收購北方民爆100%股權
格隆匯4月5日丨江南化工(002226.SZ)公佈,公司分別於2023年3月13日、2023年3月29日召開第六屆董事會第十六次會議和2023年第二次臨時股東大會,審議通過了《關於現金收購陝西北方民爆集團有限公司100%股權暨關聯交易的議案》。同意公司以現金方式收購北方特種能源集團有限公司、兵器工業股權投資(天津)有限公司及西安慶華投資有限公司持有的陝西北方民爆集團有限公司(“北方民爆”、“標的公司”)100%股權,交易金額為5.44億元。
截至目前,此次交易標的資產北方民爆100%股權已完成過户手續及相關工商變更登記手續。此次過户變更後北方民爆成為了公司全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.